809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival

Títulos similares

• 1061 The role of interleukin-9 in head and neck squamous cell carcinoma immune response and tumorigenesis
  por: Maria Lehn, et al.
  Publicado: (2023-11-01)
• Three-dimensional matrix stiffness modulates mechanosensitive and phenotypic alterations in oral squamous cell carcinoma spheroids
  por: Maulee Sheth, et al.
  Publicado: (2024-09-01)
• Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer
  por: Adam Luginbuhl, et al.
  Publicado: (2021-11-01)
• Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case–Control Study of Patients with Head and Neck Squamous Cell Carcinoma
  por: Trisha Wise-Draper, et al.
  Publicado: (2018-02-01)
• 252 Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence
  por: Trisha Wise-Draper, et al.
  Publicado: (2020-11-01)